Table 3 Association between log memory B cell responses at M7 and anti-HPV IgG concentrations after 1, 2 and 3-doses (per-protocol cohort1)

From: Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial

 

1 dose

2-doses

3-doses

Visit

N

Fold increase (95% CI)2

p-value3

N

Fold increase (95% CI)2

p-value2

N

Fold increase (95% CI)2

p-value2

Cervarix®

HPV-16

M7

144

1.45 (1.22–1.72)

<0.001

141

1.87 (1.36–2.57)

<0.001

140

2.69 (1.93–3.74)

<0.001

M12

136

1.37 (1.12–1.66)

0.002

133

2.05 (1.41–2.98)

<0.001

134

3.46 (2.31–5.17)

<0.001

M24

145

1.20 (1.00–1.42)

0.044

136

1.90 (1.37–2.63)

<0.001

134

2.29 (1.64–3.21)

<0.001

M36

142

1.21 (1.02–1.44)

0.026

140

1.93 (1.42–2.62)

<0.001

135

2.46 (1.79–3.38)

<0.001

HPV-18

M7

137

1.04 (0.85–1.26)

0.707

140

1.37 (1.04–1.81)

0.027

135

2.23 (1.63–3.04)

<0.001

M12

130

0.90 (0.73–1.13)

0.370

132

1.40 (1.03–1.89)

0.031

129

2.60 (1.84–3.68)

<0.001

M24

138

0.97 (0.79–1.19)

0.783

135

1.54 (1.15–2.05)

0.003

131

2.41 (1.75–3.31)

<0.001

M36

136

0.88 (0.72–1.09)

0.240

139

1.43 (1.08–1.91)

0.013

130

2.46 (1.77–3.42)

<0.001

Gardasil-9®

HPV-16

M7

142

1.17 (0.98–1.40)

0.086

139

1.82 (1.24–2.67)

0.002

141

1.97 (1.38–2.81)

<0.001

M12

142

1.29 (1.09–1.51)

0.003

135

1.89 (1.34–2.68)

<0.001

133

2.90 (2.09–4.01)

<0.001

M24

143

1.33 (1.11–1.58)

0.002

137

2.15 (1.49–3.12)

<0.001

136

2.71 (1.92–3.82)

<0.001

M36

137

1.28 (1.07–1.52)

0.006

138

2.18 (1.50–3.16)

<0.001

138

2.69 (1.91–3.79)

<0.001

HPV-18

M7

133

1.23 (1.02–1.50)

0.034

134

1.57 (1.17–2.09)

0.002

142

1.55 (1.21–1.98)

0.001

M12

134

1.24 (1.01–1.52)

0.037

130

1.81 (1.34–2.44)

<0.001

133

1.89 (1.45–2.46)

<0.001

M24

134

1.38 (1.11–1.72)

0.004

132

1.80 (1.30–2.50)

<0.001

137

1.87 (1.41–2.49)

<0.001

M36

129

1.35 (1.08–1.68)

0.008

133

1.94 (1.35–2.77)

<0.001

139

1.97 (1.49–2.60)

<0.001

  1. 1DoRIS participants who were ELISA antibody negative & DNA negative at baseline (pre-vaccination) for the HPV genotype under analysis. 2Increase in mean log anti-HPV IgG concentrations (IU/mL) with 1 unit increase in M7 log HPV-specific memory B cells. 3p-value from linear regression at each visit, with log IgG concentrations as the response and fixed effects for M7 log HPV-specific memory B cells, dose and their interaction.
Back to article page